To confirm an equal distribution among study groups and reduce potential bias which could limit data interpretation, we included the evaluation of pathological variables such KRAS, NRAS, and BRAF mutational status (these genes are commonly mutated in colorectal cancer, showing a strong association with therapy resistance and patient outcome), MMR genes expression: MLH1, MSH2, MSH6, and PSM2 (their loss of expression is related to MSI), and tumor proliferation status based on Ki‐67 expression. Here, MLH1 is linked to neoplasm.